WSTAM
UBX

Wilbanks Smith & Thomas Asset Management’s Unity Biotechnology UBX Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,200
Closed -$72K – 509
2021
Q1 		$72K Buy
+1,200
New +$81.8K ﹤0.01% 463

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's UBX Position: Q2 2021 in Review

Wilbanks Smith & Thomas Asset Management sold out of Unity Biotechnology (UBX) in Q2 2021, closing a stake of 1,200 shares — an estimated $72K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in UBX in Q1 2021 and held it in 1 quarter. The position peaked at $72K in Q1 2021. 98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Unity Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 1,200 Unity Biotechnology shares in Q2 2021, an estimated $72K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Unity Biotechnology in Q1 2021 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Unity Biotechnology position peaked at $72K in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q2 2021, filed 4 Aug 2021.